Sociedad Quimica y Minera de Chile S.A. Series B 3.01% $10T Sociedad Quimica y Minera de Chile S.A. A 0.26% $10T ...
Also on Saturday, Sandoz announced that its biosimilar Hyrimoz (adalimumab-adaz) was being offered under its Sandoz One Source programme, designed to provide support to patients with education ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback